Surgery Partners (SGRY) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Revenue: Approximately $849 million, up 2.7% year-over-year.

Adjusted EBITDA: Approximately $125 million, with an adjusted EBITDA margin of 14.7%. This is a slight decline from $129 million in the prior year.

Year-to-Date Performance: Net revenue of approximately $1.66 billion, up 3.6% year-over-year; adjusted EBITDA of approximately $228 million, down 2.3% year-over-year.

Same-Facility Revenue Growth: Increased 5% year-over-year, driven by a 4.8% increase in net revenue per case.

Payer Mix: Commercial payer mix declined to approximately 49%, while government payer mix increased, primarily affecting larger surgical hospitals.

2Strategic Updates and Business Highlights

Portfolio Optimization: Surgery Partners announced the pending sale of its Idaho Falls facilities to Intermountain Health, marking a significant step in its strategic review process aimed at focusing on core short-stay surgical facilities.

Physician Recruitment: 191 new physicians recruited in Q2, with a year-to-date total of 330. The revenue contribution from the 2026 cohort increased nearly 16% compared to the previous year's cohort.

De Novo Development: Six de novo facilities under construction and seven in the pipeline, focusing on high-quality health systems and physician groups.

Cost Management: Continued focus on reducing operating expenses as a percentage of revenue, with improvements noted in salaries, wages, and supplies.

3Forward Guidance and Outlook

Full-Year 2026 Guidance: Reaffirmed revenue guidance of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, excluding the impact of the Idaho Falls transaction.

Post-Transaction Expectations: Following the Idaho Falls sale, the company anticipates improved cash conversion and a reduction in consolidated debt, potentially lowering leverage by approximately 0.3 turns.

4Bad News, Challenges, or Points of Concern

Declining Adjusted EBITDA Margin: Year-to-date adjusted EBITDA margin decreased to 13.7% from 14.5% in the prior year.

Increased Government Payer Mix: The shift towards a higher government payer mix could impact profitability, particularly in larger surgical hospitals.

M&A Activity: The company has completed minimal acquisitions in 2026, falling short of its $200 million annual target, as focus has shifted to optimizing existing assets.

Competitive Pressures: Concerns about broader surgical volume trends in the industry, although the company remains focused on high-acuity procedures.

5Notable Q&A Insights

Market Dynamics: Management expressed confidence in the growth of higher-acuity procedures, particularly in orthopedics and vascular surgeries, despite broader industry concerns about surgical volumes.

Idaho Falls Transaction: The sale is seen as a critical move to simplify operations and reduce exposure to traditional acute care, with management indicating that future divestitures are not planned but will remain opportunistic.

Physician Recruitment: The company highlighted the importance of physician recruitment in driving revenue growth, with expectations that new physicians will significantly contribute to revenue in their second and third years.

Cost Management Initiatives: Management emphasized ongoing efforts to control costs, particularly in labor and supplies, and noted that no significant wage inflation pressures are currently impacting operations. Overall, Surgery Partners reported solid revenue growth in Q2 2026 while navigating challenges related to payer mix and operational efficiency. The strategic divestiture of Idaho Falls is expected to enhance the company's focus on its core surgical business and improve financial metrics moving forward.